VC Built
for Builders,
by Builders
Using a technology-first approach, OMX takes groundbreaking discoveries and grows them into scalable biotech companies.
Investing in Tomorrow’s Transformative Companies
We are at the beginning of biology revolutionizing our lives. This is enabled by data from novel Bio-Tools, Data, and Artificial Intelligence creating major new insights in biology. These insights will create the next generation of medicines, tools and solutions.
Portfolio Highlights
Delix is developing a class of novel non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles for the treatment of psychiatric and neurological indications.
Sector:
Therapeutics
Status:
Active
Freya is revolutionizing women's health through restoration of healthy vaginal microbiomes. Freya's first centers around improving the efficacy of in-vitro fertilization.
Sector:
Therapeutics
Status:
Active
Mythic has uncovered a key mechanism governing how antibody drugs interact with target cells. Using this understanding, Mythic is significantly improving upon existing FDA-approved antibody therapies for oncology, both in terms of safety and efficacy.
Sector:
Therapeutics
Status:
Active
Constructive Bio is pioneering approaches for building entirely synthetic genomes & for reprogramming the genetic code of living organisms for programmable polymer synthesis. Constructive Bio platform technologies have created virus resistant organisms, and are turning living cells into sustainable bio factories to realize the sustainable materials and therapies of the future.
Sector:
Synthetic Bio
Status:
Active
Matterworks is building a machine-learning software platform to enable users of mass spectrometry (MS) instruments to avoid chromatography steps in analyzing metabolomics samples, thereby achieving faster MS performance and covering a significantly broader range of analytes per run.
Sector:
BioTools & Diagnostics
Status:
Active
VedaBio is revolutionizing molecular biology with its breakthrough platform for near-instant molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. The CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries.
Sector:
BioTools & Diagnostics
Status:
Active
Latest News & Research
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
